Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | CTH | P32929 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890600 | 1.00 | NOS3 (0.51) | NOS3NOS1NOS2GSRCTH | |
| SCHEMBL525228 | 0.96 | NOS3 (0.55) | NOS3NOS1NOS2GSRCTH | |
| SCHEMBL31688706 | 0.96 | NOS3 (0.55) | NOS3NOS1NOS2GSRCTH | |
| SCHEMBL479185 | 0.96 | NOS3 (0.55) | NOS3NOS1NOS2GSRCTH | |
| Hydrochloric Acid SCHEMBL524956 | 0.94 | NOS3 (0.53) | NOS3NOS1NOS2GSRCTH | |
| Hydrochloric Acid SCHEMBL524957 | 0.94 | NOS3 (0.53) | NOS3NOS1NOS2GSRCTH | |
| Hydrochloric Acid SCHEMBL6873225 | 0.94 | NOS3 (0.53) | NOS3NOS1NOS2GSRCTH | |
| SCHEMBL890472 | 0.83 | NOS3 (0.51) | NOS3NOS1NOS2GSRPTGS1 | |
| SCHEMBL1316628 | 0.83 | GSR (0.52) | NOS3NOS1NOS2GSRCTH | |
| SCHEMBL4018310 | 0.83 | GSR (0.52) | NOS3NOS1NOS2GSRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171500-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250092094-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119529036-A | Conformationally stabilized RSV pre-fusion F proteins | 考尔德生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-111405907-B | Conformationally stabilized RSV pre-fusion F proteins | 考尔德生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240238369-A1 | Conformationally Specific Viral Immunogens | CALDER BIOSCIENCES INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11993633-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11926649-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-03-12 | — | — | US | disclosed |
| US-11752191-B2 | Conformationally-specific viral immunogens | CALDER BIOSCIENCES INC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | ALIA THERAPEUTICS SRL (IT) | 2023-02-23 | — | — | US | disclosed |
| US-20230053714-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-1641813-A4 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | AVATAR BIOTECHNOLOGIES INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7037894-B2 | Stabilized proteins | AVATAR MEDICAL, LLC (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1641813-A2 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | Avatar Biotechnologies, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005051975-A2 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | AVATAR BIOTECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050123530-A1 | Stabilized proteins | AVATAR MEDICAL, LLC (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050054572-A1 | Methods for obtaining molecules with reduced immunogenicity | CALDER BIOSCIENCES INC. | 2005-03-10 | — | — | US | disclosed |
| EP-1282722-A4 | STABILIZED PROTEINS | AVATAR MEDICAL L L C (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1282722-A1 | STABILIZED PROTEINS | Avatar Medical, L.L.C. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020061549-A1 | Stabilized proteins | CALDER BIOSCIENCES INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001029247-A1 | STABILIZED PROTEINS | AVATAR MEDICAL, LLC (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | RHOC, PDE6C, PDE6H | NOS3 2162/4885NOS1 3336/4885NOS2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.